The raging bull market that started at the beginning of 2023 is in jeopardy. The recent market downturn is an excellent ...

AbbVie acquired ImmunoGen and Cerevel Therapeutics in 2024 ... Analysts are also primarily bullish on AbbVie, with 17 buy or strong buy ratings, 11 holds, and an average price target of 11% ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

It came just a few days after AbbVie agreed a $10.1 billion deal to buy antibody-drug conjugate developer ImmunoGen. CNS is a key therapeutic focus for AbbVie and chief executive Richard Gonzalez ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

AbbVie didn't stop there. AbbVie acquired ImmunoGen and Cerevel Therapeutics in 2024 for $10 billion and $9 billion, respectively. The ImmunoGen deal's star is the ovarian cancer drug Elahere ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors ...